As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Vinay Torani
Advertisement
Articles by Vinay Torani
Advertisement
Latest Updated Articles
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesPublished: December 4th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
3
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
4
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model
5